Professor Colin Dayan
Prosiectau fel Prif Ymchwiliwr
- Accelerate the route to patient benefit of new interventions to preserve beta cell function in T1D - Study Plus (01.01.2023 - 28.02.2025)
- Albiglutide versus placebo in insulin-treated subjects with new-onset Type 1 Diabetes mellitus (22.01.2015 - 31.03.2020)
- A phase 1, randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of NGM217 in adults with autoimmune diabetes (11.04.2018 - 31.03.2020)
- Beta cell preservation via antigen-specific immunotherapy in type 1 diabetes: Enhanced epidermal antigen delivery systems (01.09.2012 - 31.05.2017)
- Clinical Trial (01.12.2015 - 31.03.2020)
Prosiectau fel Cyd-Ymchwiliwr
- Microneedle delivery of antigen-specific immunotherapy for type 1 diabetes (01.10.2014 - 30.09.2018)
- A new window into the immune response funding during Type 1 Diabetes (01.11.2017 - 31.05.2019)
- B cells in newly diagnosed type 1 diabetes (01.03.2012 - 31.07.2016)
- Bringing immunotherapy for type 1 diabetes into the clinic: New windows into the immune response (01.05.2018 - 30.04.2019)
- Cardiovascular disease research (01.11.2013 - 31.10.2016)